PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.

doi:10.3389/fimmu.2021.672521

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.

Frontiers in immunology - 1 Jan 2021

Parakh Sagun, Musafer Ashan, Paessler Sabrina, Witkowski Tom, Suen Connie S N Li Wai, Tutuka Candani S A, Carlino Matteo S, Menzies Alexander M, Scolyer Richard A, Cebon Jonathan, Dobrovic Alexander, Long Georgina V, Klein Oliver, Behren Andreas

Abstract excerpt

A significant number of patients (pts) with metastatic melanoma do not respond to anti-programmed cell death 1 (PD1) therapies. Identifying predictive biomarkers therefore remains an urgent need. We retrospectively analyzed plasma DNA of pts with advanced melanoma treated with PD-1 antibodies, nivolumab or pembrolizumab, for five PD-1 genotype single nucleotide polymorphisms (SNPs): PD1.1 (rs36084323, G>A), PD1.3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Biomarkers, Tumor

Share to Drug Resistance, Neoplasm

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 34177913
DOI: 10.3389/fimmu.2021.672521
PMCID: PMC8220213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.PMID 34177913Read ↗

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 MonotherapySemantic proximity Read ↗

Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma.Semantic proximity Read ↗

Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma.Semantic proximity Read ↗

A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab.Semantic proximity Read ↗

PDCD1 gene polymorphisms as regulators of T-lymphocyte activity in cutaneous melanoma risk and prognosis.Semantic proximity Read ↗

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.Semantic proximity Read ↗

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanomaSemantic proximity Read ↗

Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.Semantic proximity Read ↗

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaSemantic proximity Read ↗

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.